FUTURE MULTI BAGGER COMPANY ANALYSIS

Rama sir, your views on AVT natural products......shall I hold this stock for long term?

 

do anyone track Lincoln pharma and pincon sprit both are performing well

 

I think they will be multibeggar

 

Hi rama sir Sharon bio what's ur view it has been beaten down badly

 

pls put some light on Sharon bio stoocjeet sakti sir

 

Dear Kris ,
Mercury lab is a good small cap ...but last 5 years sales and net profit growth is slow
and very low volume traded stock (public holding is low 3,28,300 share only )

 

Sharon bio is a High Debt company and some of promoter stake is in pledge ,
jun 2015 quarter result Rs. 82.43 Cr. Loss
i dont know about latest quarterly result

 

Dear sir
i reply about sharon bio stock in my previous post ....
ALL THE BEST SIR

 

Yes brother it is one of the main problem in stock fundamental analysis ...we must depend annual reports
there is no there way , we should analyze several times before going to buy a stock ,
so always "Market Risk " is there no doubt , ex : satyam computers is best case , they showed 8000 Cr.rupees cash reserves but actually almost no cash may be 500 cr. Rs. aprox. , so so many mutual funds also take huge positions based on annual reports and job recruitment numbers all are failure at last .....
these are all main lessons ....

 

Disclaimer : This is not a Recommendation,This Primary information is only for knowing facts about company (This is Learning and Discussion Purpose only) , Don't Buy this stock based on this information , please Analyze with your own Information and Analysis.
I am not a SEBI Registered Stock Market Analyst
Data Source : Company official Website


CLARIS LIFE SCIENCES LTD

Pharma

LAST TRADED PRICE : Rs. 198.70

Eq : 54.57 Cr.

Face Value : Rs. 10

EPS : 25.42

PE RATIO : 10

ALMOST DEBT FREE COMPANY

LAST 5 YEARS SALES AND NET PROFIT GROWTH

BOOK VALUE : Rs. 157

SALES : 725 Cr.

PAT :138.69 Cr.

* Last year company repay almost all debt


Cons :

1.Dividend last 2 years company not paying any dividend

2.Some of promoters stake is in pldge

 

@RAMA MURTHY SASTRY CHALLA . Sir These numbers looks good. One more positive is Reliance MF bought a sizeable chunk on 1 oct 15.
2 things concerns me.
first, Net cash flow of the last 4 yrs are negative.
Second, from where the phase of growth will come? bottom line growth is okay as compared to some other pharma companies .

 

mainly they are focusing reducing debt so cash is used to repay almost all debts , so in my view next 2 years
company may get surplus cash reserves .......
but valuations are reasonable PE Ratio only 10

 

rama sir any idea abt pincon spirit if any pls share regards and thanks

 

In old posts in this thread discussed about this pincon spirit stock please review that ....

 

Dear nayantravels
for pincon spirit stock
page no : 2 , post no : 26 posted by Stock - artist ,

 

TECHNVISION @71.80 high risk stock that can be a multibagger. Asmall qtty taken today

 

what is the main high light points in this stock sir ?

 

Claris Lifesciences (held trading position in Oct.)

a lot of corporate governance & USFDA compliance issues, IT raid, operator driven, no real DII holding, Reliance MF buying - note, Reliance Sec came out with a report on Claris, read it https://app.investmentguruindia.com...Lifescience-Management_Meet_Update-051015.pdf

Q2 results today, take a look https://corporates.bseindia.com/xml...4D49C4_69CC_4FEA_8297_2537F94E62E3_162645.pdf

 

Innovative Tech Pack @ CMP 34.80 - listed only on BSE
Trident @ CMP 41.55

 

This company is into big data and ERP. About 37% of stake held by promoters and another 37%by SOLIX ( indian origin ) foreign promoter AND another 9.5% held by Solix related TRUSTS leaving a meagre 16% in the public. It is learnt that the company (SOLIX) has ambitious plans and working towards targeting One billion dollar revenues in the near future.Buying a small quantity may limit our risk and if the company succeeds may generate good profit .

Plz go through this link https://www.sramanamitra.com/2015/0...-competitors-solix-ceo-sai-gundavelli-part-1/